Duncan Scott

Duncan is currently the leader of the Coronavirus portfolio at the Dundee Drug Discovery Unit. He did his PhD in the laboratory of Professor Chris Abell in Cambridge, and went on to participate in and then lead fragment-based programmes targeting protein-protein interactions in a multi-disciplinary team with Profs Sir Tom Blundell, Ashok Venkitaramen and Marko Hyvonen. After this he moved to the ALBORADA Drug Discovery Institute as a medicinal chemistry team leader, where he led several drug discovery projects against Alzheimer's and other CNS diseases, both target-based and phenotypic. His interests include drug discovery, medicinal chemistry, fragment approaches and biophysics.